Greenbrook TMS Inc. (NASDAQ: GBNH), a Canada-based provider of Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray), FDA-cleared, non-invasive therapies for the treatment of Major Depressive Disorder (MDD) and other mental health disorders, in the United States, announced on Monday that it has named Peter Willett as its new chief financial officer, effective immediately.

Willett was earlier appointed as the company's interim chief financial officer. He has served as senior vice president of Finance at Greenbrook finance team. He has more than 11 years of finance experience, offering a wide range of experience and specialised knowledge regarding financial and accounting matters that are unique to the mental health services industry.

The company says that Willett has played an important role in developing and applying the financial strategies that have been successful in improving reporting its functions and cost controls. He has expertise in identifying effective processes and procedures to improve quality, accuracy, and efficiency in accounting and financial operations.